Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Conferees debate supervision, federal‑wide assurance and immunity language in HB701‑FN
Summary
Committee conferees examined whether HB 701‑FN should permit experimental treatments at satellite sites under a parent facility’s federal wide assurance, how to define “direct supervision,” and whether immunity should cover “reckless” as well as “willful” misconduct.
Committee conferees on HB 701‑FN spent an extended portion of the conference discussing who may lawfully administer certain experimental medical treatments and the statutory protections and administrative requirements for eligible facilities.
Representative Leon and several senators and house conferees debated three interlinked points: (1) whether a facility in New Hampshire may rely on a federal wide assurance (FWA) held by a parent institution in another state or by a satellite location; (2) what “direct supervision” by an eligible facility requires in practice; and (3) whether the bill’s civil immunity should include “reckless” conduct in addition to “willful misconduct.”
Several conferees said obtaining an FWA can take weeks…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
